| 時間 | 主題 | ||||
|---|---|---|---|---|---|
14:10 ~ 14:20 |
PD04-01: ALDH1L1 Overexpression Promotes Tumor Progression and Angiogenesis and Serves as a Predictor of Poor Prognosis in Urothelial Carcinoma
講者:
葉碧雯
座長:
余家政, 羅浩倫 |
葉碧雯 |
余家政, 羅浩倫 |
||
14:20 ~ 14:30 |
PD04-02: The Contribution of MRE11, RAD50, and NBS1 Genotypes to Bladder Cancer Susceptibility in mid-Taiwan
講者:
廖丞晞
座長:
余家政, 羅浩倫 |
廖丞晞 |
余家政, 羅浩倫 |
||
14:30 ~ 14:40 |
PD04-03: Urine biomarkers enables the detection of urothelial carcinoma
講者:
蔡秉軒
座長:
余家政, 羅浩倫 |
蔡秉軒 |
余家政, 羅浩倫 |
||
14:40 ~ 14:50 |
PD04-04: Urinary Extracellular Vesicles as Non-Invasive Liquid Biopsies for Predicting Metastasis in Upper Tract Urothelial Carcinoma
講者:
羅建雄
座長:
余家政, 羅浩倫 |
羅建雄 |
余家政, 羅浩倫 |
||
14:50 ~ 15:00 |
PD04-05: Real-World Efficacy and Safety of Neoadjuvant Enfortumab Vedotin plus Pembrolizumab in High-Risk Bladder and Upper Tract Urothelial Carcinoma
講者:
張家郡
座長:
余家政, 羅浩倫 |
張家郡 |
余家政, 羅浩倫 |
||
15:00 ~ 15:10 |
PD04-06: Validation of the Neoadjuvant Chemotherapy Vesical Imaging-Reporting and Data System (nacVI-RADS) in Patients with Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Enfortumab Vedotin and Pembrolizumab
講者:
張家郡
座長:
余家政, 羅浩倫 |
張家郡 |
余家政, 羅浩倫 |